CN Patent

CN113563343B — 取代的吡唑并[1,5-a]嘧啶化合物及其用途

Assigned to Hangzhou Bangshun Pharmaceutical Co Ltd · Expires 2022-05-24 · 4y expired

What this patent protects

本发明公开了一种取代的吡唑并[1,5‑a]嘧啶化合物及其用途。本发明所公开的式I化合物具有吡唑并[1,5‑a]嘧啶系列结构，对于原肌球蛋白受体(Trk)激酶具有良好的抑制效果，对体外肿瘤细胞增殖也具有良好的抑制作用。

USPTO Abstract

本发明公开了一种取代的吡唑并[1,5‑a]嘧啶化合物及其用途。本发明所公开的式I化合物具有吡唑并[1,5‑a]嘧啶系列结构，对于原肌球蛋白受体(Trk)激酶具有良好的抑制效果，对体外肿瘤细胞增殖也具有良好的抑制作用。

Drugs covered by this patent

Patent Metadata

Patent number
CN113563343B
Jurisdiction
CN
Classification
—
Expires
2022-05-24
Drug substance claim
No
Drug product claim
No
Assignee
Hangzhou Bangshun Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.